|
|
Vaccine Detail
|
Adenovirus-vectored therapeutic vaccine (Ad-Ii-E1E2E6E7) |
| Vaccine Information |
- Vaccine Name: Adenovirus-vectored therapeutic vaccine (Ad-Ii-E1E2E6E7)
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Recombinant vector vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Host Species as Laboratory Animal Model: Mouse
- Antigen: HPV16 antigens: E1, E2, E6, and E7 (Boilesen et al., 2023)
- Immunization Route: Intramuscular injection (i.m.)
- Description: The vaccine enhances CD8+ and CD4+ T-cell responses, targeting HPV16 proteins effectively. Regulatory CD4+ T cells (Tregs) were increased, potentially modulating therapeutic efficacy. The vaccine induced robust CD8+ T-cell responses, particularly to E1 and E7, and CD4+ responses to E1 and E2. High-affinity binding epitopes (IC50: 0–50 nM) dominate in E1, suggesting its strong immunogenic potential. (E1-specific CD8+ and CD4+ T-cell responses were consistently detected across all mouse models.) The vaccine reduced tumor growth and improved survival in HPV-positive C3 tumor-bearing mice, both as a monotherapy and in combination with cisplatin. No significant CD8+ responses were detected for E2 or E6 in C57BL/6 mice. The Ad-Ii-E1E2E6E7 vaccine outperformed synthetic E6/E7 peptides in terms of tumor control and survival.
|
| Host Response |
|
|
| References |
|
|
|
